secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2025-11-25T23:59:59+00:00
Accession:  0001178913-25-003949
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silexion completes toxicology studies for SIL204; Phase 2/3 trial on track for Q2 2026
--------------------------------------------------------------------------------

- Two-species toxicology studies for SIL204 confirm no systemic organ toxicity, clearing path to regulatory filings.
- Regulatory submissions planned to Israel Ministry of Health and Germany's BfArM ahead of Phase 2/3 trial.
- Phase 2/3 clinical trial in locally advanced pancreatic cancer (LAPC) expected to initiate in Q2 2026.
- CRO partner for the trial has been secured; SIL204 targets mutant KRAS oncogenes via siRNA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325003949/0001178913-25-003949-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325003949/zk2534066.htm
  HTML page:      https://secwatch.observer/filing/0001178913-25-003949

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer